NCT03436862View on ClinicalTrials.gov

Nivolumab Maintenance Therapy After Autologous Stem Cell Transplant in Hodgkin Lymphoma Pts at Relapse/Progression Risk

PHASE2CompletedINTERVENTIONAL
Enrollment

37

Participants

Timeline

Start Date

May 23, 2018

Primary Completion Date

May 5, 2022

Study Completion Date

April 4, 2023

Conditions
Hodgkin Lymphoma
Interventions
DRUG

Nivolumab

Nivolumab 240 mg IV infusion over 60 minutes given every 2 weeks for up to 6 months.

Trial Locations (6)

37203

Tennessee Oncology, Nashville

53226

Medical College of Wisconsin, Milwaukee

64132

HCA Midwest, Kansas City

78229

Texas Transplant Institute, San Antonio

78704

St. David's South Austin Medical Center, Austin

80218

Colorado Blood Cancer Institute, Denver

Sponsors

Collaborators (1)

Bristol-Myers Squibb
All Listed Sponsors
collaborator

Bristol-Myers Squibb

INDUSTRY

lead

SCRI Development Innovations, LLC

OTHER

NCT03436862 - Nivolumab Maintenance Therapy After Autologous Stem Cell Transplant in Hodgkin Lymphoma Pts at Relapse/Progression Risk | Biotech Hunter | Biotech Hunter